GeneDx is trading at $68.72, up 6.23%, with biotech and diagnostics strength potentially supporting the move.
- No confirmed GeneDx-specific announcement or fresh company catalyst was identified for October 29; next reported earnings are scheduled for November 9.
- XBI was up 1.2% at 9:49 a.m.; a market update cited a firm healthcare backdrop and supportive diagnostics read-through.
- Sector strength contrasts with the weaker broad-market context, but evidence does not establish a direct company-specific cause.